An inhibitor of ELOVL1
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

ELOVL1-27

Item No. 35323

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
1-(2-fluorophenyl)-N-[1-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]-cyclopropanecarboxamide
CAS Number
2227482-41-7
Molecular Formula
C18H14F2N4O
Formula Weight
340.3
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMSO: 2 mg/ml
λmax
289 nm
SMILES
FC1=C(C2(C(NC3=NN(C4=CC=NC(F)=C4)C=C3)=O)CC2)C=CC=C1
InChi Code
InChI=1S/C18H14F2N4O/c19-14-4-2-1-3-13(14)18(7-8-18)17(25)22-16-6-10-24(23-16)12-5-9-21-15(20)11-12/h1-6,9-11H,7-8H2,(H,22,23,25)
InChi Key
UWMKZOSESQVNAA-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $109

    Add

    5 mg

    $355

    Add

    10 mg

    $545

    Add

    25 mg

    $953

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    ELOVL1-27 is an inhibitor of ELOVL fatty acid elongase 1 (ELOVL1; IC50 = 900 nM).1 It reduces lysohexacosanoylphosphatidylcholine (LPC(C26:0)) synthesis in HEK293 cells (IC50 = 13 nM), as well as in primary fibroblasts isolated from patients with cerebral adrenoleukodystrophy (CALD) or adrenomyeloneuropathy (AMN; IC50s = 15-43 nM), neurodegenerative diseases characterized by rapid inflammatory demyelination of the CNS. ELOVL1-27 (2, 16, and 32 mg/kg) reduces blood LPC(C26:0) levels in wild-type mice and rats. It also reduces CNS levels of LPC(C26:0) in an ABCD1-/- mouse model of ALD when administered at a dose of 1 or 10 mg/kg per day for at least three months.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Come, J.H., Senter, T.J., Clark, M.P., et al. Discovery and optimization of pyrazole amides as inhibitors of ELOVL1. J. Med. Chem. 64(24), 17753-17776 (2021).